Abstract
Several clinical trials suggest that β-glucans may reduce feelings of fatigue, however the results of clinical trials are inconsistent. Additionally, no systematic reviews or meta-analyses have assessed the effects of β-glucans on fatigue. Therefore, this study investigates the effects of β-glucans on fatigue in healthy subjects through a systematic review and meta-analysis. PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to March 15, 2024. The inclusion criterion was a randomized controlled trial (RCT) investigating the effects of β-glucans on healthy subjects’ fatigue, vigor, and mood state. To assess risk of bias, we employed the Cochrane risk of bias tool. A random-effects meta-analysis was conducted for the standardized mean difference (SMD). Sixteen RCTs with a total of 1,449 participants were included, and 12 studies provided data suitable for meta-analysis. Meta-analysis revealed that β-glucans significantly reduced feelings of fatigue (SMD = −0.32, 95% CI = −0.53 to −0.12; p = 0.0021), increased vigor (SMD = 0.46, 95% CI = 0.26–0.66; p < 0.0001), and improved mood state (SMD = 0.32, 95% CI = 0.11–0.53; p = 0.0026) compared to the placebo group. The results of the systematic review and meta-analysis indicate that β-glucans may be effective in reducing feelings of fatigue in healthy individuals. However, the number of studies included is insufficient, suggesting that further clinical trials are needed to validate this effect.
Subject terms: Randomized controlled trials, Nutrition
Introduction
Fatigue is a common physiological phenomenon encompassing both physical and mental components, experienced by many individuals on a daily basis. Symptoms of fatigue include tiredness, weakness, and a lack of energy [1]. In healthy individuals, causes of fatigue are often linked to occupation, social events, and personal lifestyle [2], with significant economic implications for society [3]. Given this context, there is a growing need to develop food products scientifically proven to alleviate feelings of fatigue.
β-glucans are dietary fibers found in various sources such as mushrooms, barley, and yeast. They consist of polysaccharides composed of D-glucose through β-glycosidic linkages. The molecular structure of β-glucans varies depending on their source, with bacterial β-glucans containing β-1,3 linkages, cereal β-glucans containing β-1,3-1,4 linkages, and those from seaweeds and yeasts containing β-1,3-1,6 linkages [4]. β-glucans are categorized into grain-derived and non-grain-derived types based on their source. Grain-derived β-glucans have been associated with cholesterol and blood sugar level reduction, whereas non-grain-derived β-glucans are known for their immunomodulatory effects [5]. Receptors for β-glucans, such as Dectin-1 and complement receptor 3 (CR3), have been identified [6]. It has been reported that binding of β-glucans to Dectin-1 activates immune cells, thereby inducing innate and acquired immunity [7].
Several clinical trials have investigated the effects of β-glucans on fatigue. In a study involving marathon runners, the administration of 500 mg of yeast-derived β-glucan per day for four weeks significantly reduced feelings of fatigue compared to the placebo group [8]. Similarly, in healthy subjects experiencing fatigue in daily life, the consumption of 350 mg of euglena-derived β-glucan per day for four weeks led to a significant reduction in both physical and mental fatigue compared to the placebo group, although no significant difference was observed in overall fatigue [9]. Conversely, in healthy subjects with LDL-cholesterol levels ranging from 3 to 5 mmol/L, the administration of 3000 mg of oat-derived β-glucan per day for four weeks did not result in a significant difference in the prevalence and severity of fatigue compared to the placebo group [10]. Thus, while various clinical trials have been conducted on the effects of β-glucans on fatigue, the results have shown inconsistency.
Despite numerous systematic reviews focusing on β-glucans, none have specifically addressed their effects on fatigue. Previous studies have explored β-glucans’ role as a biomarker in diagnosis [11], their potential as therapeutic adjuvants in cancer patients [12], their impact on blood glucose and lipid levels [13], and their effects on upper respiratory tract infections [14]. However, the impact of β-glucans on fatigue remains unclear, as no systematic review has specifically examined this aspect. Understanding the effects and mechanisms of β-glucans on fatigue could offer novel strategies for alleviating fatigue symptoms. Therefore, this study aimed to investigate the effects of β-glucans on fatigue in healthy subjects through a systematic review and meta-analysis.
Materials and methods
This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15].
Search strategies
PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL) were systematically searched from their inception to March 15, 2024, with no language restrictions applied. The search terms were comprised of three groups: (1) β-glucan, (2) Randomized Controlled Trial, and (3) fatigue. The detailed search strategy for this systematic review and meta-analysis is provided in the Supplementary Material (Supplementary Table S1). Additionally, hand searches were conducted for comprehensive coverage.
Study selection
Two researchers (MM and KN) independently conducted the study selection process. Any discrepancies were resolved through discussion with a third researcher (KH). The inclusion criteria were based on the PICOS (patients, intervention, comparison, outcomes, and study design) framework. The population included healthy subjects, with no restrictions on age, gender, or ethnicity, while individuals suffering from disease were excluded. The intervention involved the oral intake of foods and supplements containing β-glucans, with no limitations on the source, amount, or duration of β-glucan intake. The comparison control group was not restricted. Outcomes comprised studies assessing the effects of β-glucans on fatigue, vigor, and mood state. The study design was restricted to randomized controlled trials. Animal studies, review articles, and studies where β-glucans were not the sole dietary intake were excluded.
Data extraction
The following data were extracted from the included articles: author, country, year of publication, target population characteristics (including age), intervention and control details, number of participants, β-glucan characteristics (source, intake, duration), and outcome scale and results (specifically fatigue, vigor, and mood state). To ensure accuracy and prevent misinterpretation, special attention was paid to the direction of the effect of the scales used in each study. The primary outcomes analyzed were fatigue, vigor, and mood state scores following β-glucan and placebo interventions. In cases where results were presented graphically, they were quantified using WebPlotDigitizer [16]. Data extraction and conversion adhered to the recommendations outlined in the Cochrane Handbook [17]. For data presented as standard errors (SE), the standard deviation (SD) was calculated by multiplying the SE by the square root of the number of samples. For data presented with 95% confidence intervals, SD was obtained by dividing the width of the confidence interval by 3.92 and multiplying by the square root of the sample size. For data reporting the difference in means (MD) between groups with a given p-value, the t statistic was obtained from the t distribution table and converted to SD by dividing MD by the t statistic; the same SD was applied to both groups. If SD was not provided or calculable, SD from studies utilizing the same scale was utilized, with preference given to the mean if multiple studies used the same scale.
Quality assessment
Risk of bias in randomized trials was assessed using the Cochrane risk of bias tool for randomized trials (RoB2) [18]. This assessment covered five domains: bias risk arising from randomization processes, deviations from intended interventions, missing outcome data, outcome measurement, and selection of reported results. For crossover trials, bias risk from period and carryover effects was also evaluated. Overall bias risk was categorized as follows: (1) Low risk of bias: No bias concerns across all domains. (2) Some concerns: At least one area with potential bias concerns. (3) High risk of bias: At least one domain presents a high risk of bias.
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was employed to evaluate the certainty of evidence for each outcome [19, 20]. Since the study design is a randomized controlled trial, the certainty of evidence starts as high and is then evaluated based on five domains that may lower the grade: risk of bias, inconsistency, indirectness, imprecision, and publication bias. Certainty of evidence was graded as high, moderate, low, or very low.
Data synthesis and statistical analysis
Data analysis was conducted using the meta package [21] of R version 4.2.1 (R Core Team, Vienna). A random-effects meta-analysis was performed to estimate the standardized mean differences (SMD) between the β-glucan intervention and placebo groups. When multiple post-intervention data points were available, outcomes reported at the end of the intervention period were utilized. In cases where there were different β-glucan intake groups within a study, data from the group with the highest intake were included in the analysis. For crossover studies, due to insufficient information, data from both intervention and control periods were combined and treated as if they were from parallel studies. We conducted a subgroup analysis based on the outcome evaluation methods. Heterogeneity across studies was assessed using the I2 statistic. Publication bias was evaluated using funnel plots, Egger’s test, and Begg’s test. The significance level for statistical tests was set at 0.05, and a confidence level of 95% was applied to confidence intervals (CI).
Results
Study selection
Following the PRISMA guidelines [15], the process of study selection is depicted in Fig. 1. The literature search identified a total of 571 studies, comprising 233 articles from PubMed, 247 from Web of Science, 88 from CENTRAL, and 3 from Handsearching. After removing duplicates, 477 unique studies remained. Subsequently, 394 studies were excluded after screening based on title and abstract, resulting in 83 studies for further evaluation. Upon full-text screening, 67 studies were excluded, ultimately leaving 16 studies for inclusion in the systematic review. Among them, 12 studies were eligible for the meta-analysis.
Fig. 1. PRISMA flow diagram of study selection.
PRISMA flow diagram summarizing the results of the search and selection processes.
Study characteristics
Table 1 presents the characteristics of the included studies. These studies were conducted across various countries, including Canada, Japan, the USA, Norway, and Germany, spanning publication years from 2009 to 2022, with a total coverage of 1449 individuals. Although the target population across studies was generally healthy, specific characteristics varied. For instance, one study focused on individuals with qi deficiency [22], another on those with LDL-cholesterol levels between 3 and 5 mmol/L [10], and additional studies targeted individuals with decreased vitality, sleep quality [23], feelings of fatigue [9], engagement in aerobic or endurance exercise [24, 25], recurrent upper respiratory tract infections [26], marathon runners [8, 27], allergies such as ragweed or hay fever [28], and varying levels of psychological stress [29, 30]. Furthermore, one study focused on individuals with a history of colds [31]. In all cases, the comparison group received a placebo. Study designs included 13 randomized, double-blinded, placebo-controlled parallel studies, and three randomized, double-blinded, placebo-controlled crossover studies. The sources of β-glucans varied, including oats, yeast, euglena, shiitake mushroom, and combinations thereof. Daily intake ranged from 1 mg to 3000 mg, with durations varying from 10 days to 16 weeks. Fatigue, vitality, and mood state were the primary outcomes assessed, utilizing various measurement tools such as the Patient-Reported Outcomes Measurement Information System (PROMIS), Symptoms Questionnaire, Short-Form Health Survey (SF-12/SF-36), Visual Analogue Scale (VAS), Profile of Mood States (POMS), and Wisconsin Upper Respiratory Symptom Survey (WURSS-24). Additionally, during the intake period, specific tasks or exercises were performed in some studies, including the Uchida-Kraepelin test [32], two-back task, and advanced trail making test (ATMT) [33], as well as treadmill exercises at 55% maximal oxygen uptake in hot and humid conditions [24].
Table 1.
Characteristics in the included studies.
| Study | Country | Participants | Agea | Grouping | Dosageb | N c | Duration | Outcome | Design |
|---|---|---|---|---|---|---|---|---|---|
| Wu [22] | Canada | Healthy subjects with severity score of protective qi deficiency >1.8 | 18 ~ 65 | Yeast, Reishi, Shiitake (Proglucamune®) | ~200 mg | 70 | 12 weeks | PROMIS (mental health) | RCT |
| Placebo | 68 | ||||||||
| Wolever [10] | Canada | Healthy subjects with LDL-cholesterol between 3.00 and 5.00 mmol/L | 47.6 ± 11.4 | Oat β-glucan | 3000 mg | 96 | 4 weeks | Symptoms Questionnaire (Fatigue) | RCT |
| Placebo | 95 | ||||||||
| Nakashima [23] | Japan | Healthy subjects with reduced motivation based on the vitality measured by SF-36 and poor quality of sleep based on the PSQI total score | 48.0 ± 9.7 | (Euglena gracilis powder) | (3000 mg) | 20 | 12 weeks | SF36 (vitality) | RCT |
| 46.0 ± 10.7 | (Euglena gracilis powder) | (1000 mg) | 20 | ||||||
| 47.8 ± 11.5 | (Euglena gracilis powder) | (500 mg) | 19 | ||||||
| 47.3 ± 9.5 | Placebo | 18 | |||||||
| Kawano [9] | Japan | Healthy subjects with fatigue sensation in daily life | 49.2 ± 6.5 | Paramylon (Euglena gracilis EOD-1) | 350 mg | 25 | 4 weeks | VAS (Overall Fatigue, Physical Fatigue, Mental Fatigue) | RCT |
| 48.9 ± 10.3 | Placebo | 27 | |||||||
| Zabriskie [24] | USA | Healthy subjects who reported performing some form of aerobic exercise at least twice per week for the last 12 months | 29.9 ± 7.7 | Yeast β-glucan (Yestimun®) | 250 mg | 31 | 13 days | POMS (Fatigue, Vigor, Total Mood Disturbance) | RCT-Cross over |
| Placebo | |||||||||
| Aldwinckle [35] | Norway | Healthy subjects | / | Lentinan (Lentinex®) | 1–2 mg | 42 | 4 weeks | VAS (well-being) | RCT |
| Placebo | 14 | ||||||||
| Evans [25] | Canada | Healthy subjects who perform 1.5–3 h/day of endurance exercise or sport, 5–6 days/week | 46.8 ± 13.2 | Algal β-glucan (BetaViaTM Complete) | 367 mg | 13 | 90 days | WURSS-24 (Feeling tired) | RCT |
| 42.9 ± 12.3 | Placebo | 14 | |||||||
| Ishibashi [36] | Japan | Healthy men | 30 ~ 70 | Paramylon (Euglena gracilis EOD-1) | 350 mg | 7 | 4 weeks | SF-36v2 (energy/vitality, mental health, MCS) | RCT-Cross over |
| Placebo | |||||||||
| Dharsono [26] | Germany | Healthy subjects with at least three URTIs during the last year | 37.6 ± 14.3 | Yeast β-glucan (Yestimun®) | 900 mg | 145 | 16 weeks | SF-12 (psychological sum score) | RCT |
| 40.5 ± 16.4 | Placebo | 146 | |||||||
| Ojiri [47] | Japan | Healthy subjects who have a non-strenuous daily lifestyle | 22.8 ± 2.2 | Yeast β-glucan (Wellmune®) | 300 mg | 14 | 10 days | POMS (Fatigue, Vigor) | RCT-Cross over |
| Placebo | |||||||||
| McFarlin [27] | USA | Marathon runners | 34 ± 9 | Soluble yeast β-glucan | 250 mg | 74 | 28 days | POMS (Global Mental Health) | RCT |
| 34 ± 11 | Insoluble yeast β-glucan | 250 mg | 73 | ||||||
| 35 ± 11 | Placebo | 35 | |||||||
| Talbott [28] | USA | Subjects self-described “moderate” sufferers of ragweed allergy or considered themselves to have “hay fever” | 36 ± 11 | Yeast β-glucan (Wellmune WGP®) | 250 mg | 24 | 4 weeks | POMS (Fatigue, Vigor, Global Mood States), | RCT |
| 39 ± 9 | Placebo | 24 | |||||||
| Talbott [29] | USA | Healthy women with moderate levels of psychological stress with a score of 6-10 on the stress survey | 41 ± 11 | Yeast β-glucan (Wellmune WGP®) | 250 mg | 39 | 12 weeks | POMS (Fatigue, Vigor, Global Mood States) | RCT |
| Placebo | 38 | ||||||||
| Talbott [30] | USA | Healthy subjects with moderate levels of psychological stress with a score of 6-10 to high levels of psychological stress with a score of 10 or more in the stress survey | 39 ± 11 | Yeast β-glucan (Wellmune WGP®) | 500 mg | 50 | 4 weeks | POMS (Fatigue, Vigor) | RCT |
| Yeast β-glucan (Wellmune WGP®) | 250 mg | 50 | |||||||
| Placebo | 50 | ||||||||
| Talbott [8] | USA | Marathon runners | 36 ± 9 | Yeast β-glucan (Wellmune WGP®) | 500 mg | 25 | 4 weeks | POMS (Fatigue, Vigor, Global Mood State) | RCT |
| Yeast β-glucan (Wellmune WGP®) | 250 mg | 25 | |||||||
| Placebo | 25 | ||||||||
| Feldman [31] | USA | Healthy subjects with at least 1 self-reported cold in the last 12 months prior to screening | 30 ± 11 | Yeast β-glucan (Wellmune WGP®) | 500 mg | 17 | 12 weeks | ・Diary (Total Tiredness) | RCT |
| 36 ± 16 | Placebo | 16 | ・SF-36v2 |
RCT a randomized, double-blind, placebo-controlled, parallel study, PROMIS Patient-Reported Outcomes Measurement Information System, SF-12/SF-36 Short-Form Health Survey, VAS Visual Analogue Scale, POMS Profile of Mood States, WURSS-24 Wisconsin Upper Respiratory Symptom Survey.
a Age is presented as means ± SD.
bDosage is per day.
cN is sample size.
Risk of bias in the included studies
Figure 2 illustrates the risk of bias assessed using the Cochrane risk-of-bias tool [18]. Overall, two studies were deemed to have a low risk of bias, while 13 studies were categorized as having some concerns, and one study was considered to have a high risk of bias. Concerning bias related to the randomization process, seven studies raised concerns due to insufficient information. However, all studies demonstrated a low risk of bias regarding deviations from intended interventions, missing outcome data, and measurement of outcomes. Regarding bias in the selection of reported results, 13 studies were noted to have some concerns, with one study assessed as having a high risk of bias, as it reported only partial results for SF-36 and POMS2. Additionally, two studies were identified as having some concerns regarding bias arising from period and carryover effects.
Fig. 2. Risk of bias in the included studies.
Green cycle: low risk, yellow cycle: some concerns, red cycle: high risk.
The certainty of the evidence was evaluated using GRADEpro GDT [34], as detailed in Supplementary Table S2. Certainty for fatigue and vigor outcomes was assessed as low, while certainty for mood state was deemed moderate.
Effects of β-glucans
Table 2 summarizes the effects of β-glucans on fatigue, vigor, and mood state. Among the ten studies evaluating β-glucans’ effects on fatigue, four demonstrated significantly lower fatigue scores in the β-glucans group compared to the placebo group [8, 9, 25, 30]. These studies targeted populations with mental health issues or regular exercisers, utilized non-grain derived euglena or yeast as sources of β-glucans, administered doses ranging from 250 mg to 500 mg, and had intake durations of four weeks or longer. Among the nine studies evaluating the effects of β-glucans on vigor, three demonstrated significantly higher vigor scores in the β-glucan group compared to the placebo group [8, 29, 30]. These studies targeted populations with mental health issues or regular exercisers, utilized non-grain derived yeast as the source of β-glucans, administered doses ranging from 250 mg to 500 mg, and had intake durations of four weeks or longer. Of the ten studies evaluating the effects of β-glucans on mood state, seven demonstrated significantly higher mood state scores in the β-glucan group compared to the placebo group [8, 22, 26, 28, 29, 35, 36].
Table 2.
Effects on fatigue, vigor, and mood state.
| Study | Outcome |
|---|---|
| Wu [22] | Mood state: The “mental health” score showed no significant difference between the two groups at baseline. The “mental health” score improvement during the intervention period showed limited improvement in the placebo group, whereas a large increase in the β-glucan group was observed. The “mental health” score after 56, 70, and 84 days of intervention showed significantly higher values in the β-glucan group compared to the placebo group (p < 0.01). |
| Wolever [10] | Fatigue: |
| • The prevalence of fatigue showed no significant difference between the two groups at baseline. The prevalence of fatigue after four weeks of intervention showed no significant difference between the two groups. The prevalence of fatigue after four weeks of intervention showed a significantly lower prevalence in the β-glucan group compared to the baseline (p < 0.05). | |
| • The severity of fatigue after the intervention showed no significant difference between the two groups. The severity of fatigue after four weeks of intervention showed a significant reduction in the β-glucan group compared to the pre-intervention (p < 0.05). | |
| Nakashima [23] | Vigor: The “vitality” score showed no significant difference between the two groups at baseline. The “vitality” score after 12 weeks of intervention showed a higher value in the β-glucan group (Euglena gracilis powder: 3000 mg) compared to the placebo group. |
| Kawano [9] | Fatigue: |
| • The “Overall Fatigue” score showed no significant difference between the two groups at baseline. The change in the “Overall Fatigue” score before and after the intervention showed a lower value in the β-glucan group compared to the placebo group. The “Overall Fatigue” score after four weeks of intervention showed a significantly lower value in the β-glucan group compared to baseline (p < 0.01). | |
| • The change in the “Physical Fatigue” score before and after the intervention showed a significantly lower value in the β-glucan group compared to the placebo group (p < 0.05). The “Physical Fatigue” score after four weeks of intervention showed a significantly lower value in the β-glucan group compared to baseline (p < 0.01). | |
| • The change in the “Mental Fatigue” score before and after the intervention showed a significantly lower value in the β-glucan group compared to the placebo group (p < 0.05). | |
| Zabriskie [24] | Fatigue: The “Fatigue” score showed no significant interaction effect (group × time). The “Fatigue” score after 72 h of exercise showed a significantly lower value in both the β-glucan and placebo groups compared to the score after 0 h of exercise, respectively (p < 0.05). The “Fatigue” score after 2 h of exercise showed a significantly lower value in the β-glucan group compared to the score after 0 h of exercise (p < 0.05). |
| Vigor: The “Vigor” score showed a significant interaction effect (group × time) (p = 0.04). The “Vigor” score after 72 h of exercise showed a significantly lower value in the placebo group compared to the pre-exercise score (p < 0.05). | |
| Mood state: The “Total Mood Disturbance” score showed a significant interaction effect (group × time) (p = 0.007). The “Total Mood Disturbance” score after 72 h of exercise showed significant improvement in the placebo group compared to the score before and 0 h after exercise (p < 0.05). The “Total Mood Disturbance” score after 2 h of exercise showed significant improvement in the β-glucan group compared to the score after 0 h of exercise (p < 0.05). | |
| Aldwinckle [35] | Mood state: The “well-being” score after four weeks of intervention showed improvement in the β-glucan group compared to the placebo group, and the degree of improvement in the β-glucan group showed significant improvement in subjects with lower initial well-being (p = 0.0004). |
| Evans [25] | Fatigue: |
| • The number of days of fatigue felt from day 1 to day 30 showed a significantly lower value in the β-glucan group compared to the placebo group (p = 0.019). The number of days of fatigue felt from day 1 to day 90 showed a lower value in the β-glucan group compared to the placebo group. | |
| • The severity of fatigue from day 1 to day 30 showed a significantly lower value in the β-glucan group compared to the placebo group (p = 0.012). The severity of fatigue from day 1 to day 90 showed a lower value in the β-glucan group compared to the placebo group. | |
| Ishibashi [36] | Vigor: The “energy/vitality” score after four weeks of intervention showed a higher value in the β-glucan group compared to the pre-intervention. The placebo group showed a lower value compared to the pre-intervention. |
| Mood state: | |
| • The “mental health” score after four weeks of intervention showed a significantly higher value in the β-glucan group compared to the pre-intervention (p < 0.05). The placebo group showed a lower value compared to the pre-intervention. | |
| • The “Mental Component Summary” score after four weeks of intervention showed a significantly higher value in the β-glucan group compared to the placebo group (p < 0.05). | |
| Dharsono [26] | Mood state: |
| • The “psychological sum score” score showed no significant difference between the two groups at baseline. The “psychological sum score” score after 16 weeks of intervention showed a significantly lower value in the placebo group compared to baseline (p = 0.0011). | |
| • The change in “psychological sum score” before and after the intervention showed a significantly lower value in the placebo group compared to the β-glucan group (p = 0.038). | |
| Ojiri [47] | Fatigue: The “Fatigue” score after ten days of intervention showed a significantly lower value in the β-glucan group compared to baseline (p < 0.05). The placebo group showed a higher value compared to baseline. |
| Vigor: The “Vigor” score after ten days of intervention showed a higher value in the β-glucan group compared to the baseline. The placebo group showed a lower value compared to baseline. | |
| McFarlin [27] | Mood state: The “Global Mental Health” score showed no significant difference between the two groups. |
| Talbott [28] | Fatigue: The “Fatigue” score after four weeks of intervention showed no significant difference between the two groups. The “Fatigue” score after four weeks of intervention showed a significantly lower value in the β-glucan group compared to the pre-intervention (p < 0.05). |
| Vigor: The “Vigor” score after four weeks of intervention showed no significant difference between the two groups. The “Vigor” score after four weeks of intervention showed a significantly higher value in the β-glucan group compared to the pre-intervention (p < 0.05). | |
| Mood state: The “Global Mood States” score after four weeks of intervention showed significant improvement in the β-glucan group compared to the pre-intervention(p < 0.05). | |
| Talbott [29] | Fatigue: The “Fatigue” score after 12 weeks of intervention showed a lower value in the β-glucan group compared to the placebo group. |
| Vigor: The “Vigor” score after 12 weeks of intervention showed a significantly higher value in the β-glucan group compared to the placebo group (p < 0.01). | |
| Mood state: The “Global Mood States” score after 12 weeks of intervention showed significant improvement in the β-glucan group compared to the placebo group (p < 0.05). | |
| Talbott [30] | Fatigue: |
| • The “Fatigue” score after 2 and 4 weeks of intervention showed a significantly lower value in the β-glucan group (yeast β-glucan: 500 mg) compared to the placebo group (p < 0.05). | |
| • The “Fatigue” score after four weeks of intervention showed a significantly lower value in the β-glucan group (yeast β-glucan: 250 mg) compared to the placebo group (p < 0.05). | |
| Vigor: The “Vigor” score after 2 and 4 weeks of intervention showed a significantly higher value in the β-glucan group (yeast β-glucan: 500 mg) compared to the placebo group (p < 0.05). | |
| Talbott [8] | Fatigue: |
| • The “Fatigue” score after 2 and 4 weeks of intervention showed a significantly lower value in the β-glucan group (yeast β-glucan: 500 mg) compared to the placebo group (p < 0.05). | |
| • The “Fatigue” score after four weeks of intervention showed a significantly lower value in the β-glucan group (yeast β-glucan: 250 mg) compared to the placebo group (p < 0.05). | |
| Vigor: The “Vigor” score after 2 and 4 weeks of intervention showed a significantly higher value in the β-glucan group (yeast β-glucan: 500 mg) compared to the placebo group (p < 0.05). | |
| Mood state: | |
| • The “Global Mood State” score after 2 and 4 weeks of intervention showed significant improvement in the β-glucan group (yeast β-glucan: 500 mg) compared to the placebo group (p < 0.05). | |
| • The “Global Mood State” score after four weeks of intervention showed significant improvement in the β-glucan group (yeast β-glucan: 250 mg) compared to the placebo group (p < 0.05). | |
| Feldman [31] | Fatigue: The number of days of fatigue felt during the intervention period showed no significant difference between the two groups. |
| Vigor: The SF-36 score showed no significant difference between the two groups. | |
| Mood state: The SF-36 score showed no significant difference between the two groups. |
Meta-analysis
Of the included studies, seven reported post-intervention fatigue scores, eight reported post-intervention vigor scores, and six reported post-intervention mood state scores. Other studies did not present data suitable for inclusion in the analysis. Comparative analysis revealed that β-glucans significantly reduced feelings of fatigue compared to placebo (SMD = −0.32, 95% CI = −0.53 to −0.12, p = 0.0021, I2 = 0%) (Fig. 3). Furthermore, β-glucans significantly increased vigor compared to placebo (SMD = 0.46, 95% CI = 0.26–0.66; p < 0.0001, I2 = 0%) (Fig. 4), and improved mood state significantly (SMD = 0.32, 95% CI = 0.11 to 0.53; p = 0.0026, I2 = 30%) (Fig. 5).
Fig. 3.
Forest plot on fatigue.
Fig. 4.
Forest plot on vigor.
Fig. 5.
Forest plot on mood state.
Analysis of funnel plots and Begg and Egger tests indicated no evidence of publication bias (p > 0.1) (Supplementary Fig. S1).
Subgroup analysis
Subgroup analyses were conducted based on outcome evaluation methods for fatigue, vigor, and mood state. Meta-analysis was performed only on studies where the evaluation method was POMS, as the number of studies in other subgroups was two or fewer.
Compared to the placebo group, β-glucans significantly reduced feelings of fatigue (SMD = −0.35, 95% CI = −0.58 to −0.12, p = 0.0031, I2 = 0%) (Supplementary Fig. S2). Furthermore, β-glucans significantly increased vigor compared to placebo (SMD = 0.43, 95% CI = 0.22–0.63; p < 0.0001, I2 = 0%) (Supplementary Fig. S3), and significantly improved mood state compared to placebo (SMD = 0.35, 95% CI = 0.09–0.60; p = 0.0082, I2 = 0%) (Supplementary Fig. S4).
Discussion
This study delved into the effects of β-glucans on fatigue across 16 studies involving healthy subjects. A meta-analysis based on 12 of these studies revealed significant reductions in feelings of fatigue (SMD = −0.32, 95% CI = −0.53 to −0.12; p = 0.0021), significant increases in vigor (SMD = 0.46, 95% CI = 0.26–0.66; p < 0.0001), and significant improvements in mood state (SMD = 0.32, 95% CI = 0.11–0.53; p = 0.0026). These findings suggest that β-glucans are effective in alleviating fatigue among healthy individuals.
To effectively reduce feelings of fatigue, it may be necessary to take β-glucans for at least four weeks. Additionally, there may be potential benefits for individuals under physical or psychological stress, such as those dealing with mental health issues or engaging in regular exercise.
Strenuous exercise has been associated with adverse effects on various immune parameters, potentially increasing susceptibility to infections and other ailments [37]. Similarly, excessive stress can impact the autonomic nervous and immune systems, leading to poor sleep quality and reduced work efficiency [38, 39]. β-glucans derived from yeast have been shown to activate immune cells and promote the production of cytokines and antibodies [40, 41], which may contribute to their fatigue-reducing effects. β-glucans are recognized via receptors such as Dectin-1 and CR3, which activate innate and adaptive immunity [40]. Additionally, studies have indicated associations between fatigue and immune parameters such as sIgA concentrations, further supporting the immunostimulatory role of β-glucans [42, 43]. Moreover, β-glucans sourced from euglena have demonstrated significant increases in sIgA concentration secretion rates in healthy subjects [36], reinforcing their potential in mitigating fatigue through immune modulation.
Interestingly, while studies involving individuals with moderate psychological stress showed non-significant group differences in fatigue scores [29], those with moderate to severe psychological stress exhibited significant group differences [30]. This suggests that as psychological stress levels intensify, the impact of β-glucans on fatigue may become more pronounced.
When synthesizing results, it’s essential to consider variations in outcome assessment methods. In this study’s meta-analysis, the same concepts (such as fatigue and vigor) were evaluated using different methods. It is recommended that when synthesizing results, differing evaluation methods for the same concepts should not be relied upon as the sole approach [44]. Therefore, subgroup analyses based on differences in outcome evaluation methods were conducted. Meta-analysis of studies utilizing the Profile of Mood States (POMS) scale demonstrated that β-glucans significantly reduced feelings of fatigue, increased vigor, and improved mood state compared to placebo. These findings suggest the effectiveness of β-glucans in alleviating feelings of fatigue among healthy individuals.
Furthermore, oxidative stress and antioxidant capacity measurements offer valuable insights into fatigue status [45]. In a study evaluating oxidative stress, markers of antioxidant capacity (BAP) and BAP/d-ROMs ratio were significantly higher in the β-glucan group compared to placebo at four weeks post-intervention. Moreover, the change in BAP levels before and after the intervention was also significantly higher in the β-glucan group [9]. Additionally, Salecan, a β-glucan derived from soil bacteria, has been shown to modulate antioxidant defense mechanisms in animal models [46]. These findings suggest that the antioxidant properties of β-glucans may contribute to their fatigue-reducing effects.
Several limitations warrant consideration in interpreting the findings of this study. Firstly, heterogeneity among studies, stemming from differences in target populations, sources of β-glucans, intake regimens, durations, and outcome measures, may have influenced result accuracy. Future research, including meta-regression analysis, should explore optimal β-glucan intake strategies. Secondly, concerns regarding bias risk and publication bias exist. Only two studies were classified as “low risk” for overall bias among the included studies. Although Begg and Egger tests did not reveal significant differences, the limited number of studies precludes definitive conclusions regarding publication bias. Lastly, the number of studies and sample sizes in this analysis may be insufficient. Further clinical trials with larger sample sizes are warranted to validate the findings and provide robust evidence for the efficacy of β-glucans in managing fatigue.
Conclusion
In conclusion, the findings from this systematic review and meta-analysis suggest that β-glucans hold promise as a potential intervention for reducing feelings of fatigue among healthy individuals. However, given the limitations identified, including heterogeneity among studies and concerns regarding bias risk and publication bias, further clinical trials are necessary to confirm and validate these findings. Additionally, considering the limited number of studies included in this analysis, larger-scale trials are warranted to provide more robust evidence regarding the efficacy of β-glucans in fatigue management.
Supplementary information
Author contributions
MM has first authorship. MM and KH designed the study. MM and KN searched the databases and screened papers for inclusion. MM interpreted and analyzed the data. KM contributed to statistical advice and support. MM and KH drafted the manuscript. All authors reviewed and approved the final manuscript.
Data availability
The data utilized for all analyzes conducted in this manuscript are available from the figures and tables presented herein. Furthermore, the R package used for statistical analyses is accessible online, ensuring transparency and reproducibility of the findings.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
The online version contains supplementary material available at 10.1038/s41430-025-01567-4.
References
- 1.Landmark-Høyvik H, Reinertsen KV, Loge JH, Kristensen VN, Dumeaux V, Fosså SD, et al. The genetics and epigenetics of fatigue. PMR. 2010;2:456–65. [DOI] [PubMed] [Google Scholar]
- 2.Engberg I, Segerstedt J, Waller G, Wennberg P, Eliasson M. Fatigue in the general population- associations to age, sex, socioeconomic status, physical activity, sitting time and self-rated health: the northern Sweden MONICA study 2014. BMC Public Health. 2017;17:654. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Reynolds KJ, Vernon SD, Bouchery E, Reeves WC. The economic impact of chronic fatigue syndrome. Cost Eff Resour Alloc. 2004;2:4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Kaur R, Sharma M, Ji D, Xu M, Agyei D. Structural features, modification, and functionalities of beta-glucan. Fibers. 2020;8:1. [Google Scholar]
- 5.Murphy EJ, Rezoagli E, Major I, Rowan NJ, Laffey JG. β-Glucan metabolic and immunomodulatory properties and potential for clinical application. J Fungi. 2020;6:356. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Vetvicka V, Vetvickova J. Physiological Effects of Different Types of Β-Glucan. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151:225–31. [DOI] [PubMed] [Google Scholar]
- 7.Saijo S, Fujikado N, Furuta T, Chung SH, Kotaki H, Seki K, et al. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol 2007;8:39–46. [DOI] [PubMed] [Google Scholar]
- 8.Talbott S, Talbott J. Effect of BETA 1, 3/1, 6 GLUCAN on upper respiratory tract infection symptoms and mood state in marathon athletes. J Sports Sci Med. 2009;8:509–15. [PMC free article] [PubMed] [Google Scholar]
- 9.Kawano T, Naito J, Nishioka M, Nishida N, Takahashi M, Kashiwagi S, et al. Effect of food containing paramylon derived from Euglena gracilis EOD-1 on fatigue in healthy adults: a randomized, double-blind, placebo-controlled, parallel-group trial. Nutrients. 2020;12:3098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Wolever TMS, Rahn M, Dioum EH, Jenkins AL, Ezatagha A, Campbell JE, et al. Effect of oat β-glucan on affective and physical feeling states in healthy adults: evidence for reduced headache, fatigue, anxiety and limb/joint pains. Nutrients. 2021;13:1534. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.White SK, Schmidt RL, Walker BS, Hanson KE. (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people. Cochrane Database Syst Rev. 2020;7:CD009833. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Zhao C, Yan H, Pang W, Wu T, Kong X, Li X, et al. Lentinan combined with cisplatin for the treatment of non-small cell lung cancer. Medicine. 2021;100:e25220. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Zhu X, Sun X, Wang M, Zhang C, Cao Y, Mo G, et al. Quantitative assessment of the effects of beta-glucan consumption on serum lipid profile and glucose level in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis. 2015;25:714–23. [DOI] [PubMed] [Google Scholar]
- 14.Zhong K, Liu Z, Lu Y, Xu X. Effects of yeast β-glucans for the prevention and treatment of upper respiratory tract infection in healthy subjects: a systematic review and meta-analysis. Eur J Nutr. 2021;60:4175–87. [DOI] [PubMed] [Google Scholar]
- 15.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Rohatgi A WebPlotDigitizer. Version 4.6. https://automeris.io/WebPlotDigitizer (2024). Accessed 1 Nov 2023.
- 17.Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2023. https://training.cochrane.org/handbook/current. [DOI] [PMC free article] [PubMed]
- 18.Higgins JPT, Savovic J, Page MJ, Sterne JAC Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool?authuser=0.
- 19.Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Schunemann H, Brozek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group. 2013. https://guidelinedevelopment.org/handbook.
- 21.Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Wu JR, Cheng HJ, Shi JP, Yin WD, Wang J, Ou XQ, et al. β -glucan improves protective Qi status in adults with protective Qi deficiency-a randomized, placebo-controlled, and double-blinded trial. Chin J Integr Med. 2022;28:394–402. [DOI] [PubMed] [Google Scholar]
- 23.Nakashima A, Yamada K, Iwata O, Sugimoto R, Atsuji K, Ogawa T. β-glucan in foods and its physiological functions. J Nutr Sci Vitaminol. 2018;64:8–17. [DOI] [PubMed] [Google Scholar]
- 24.Zabriskie HA, Blumkaitis JC, Moon JM, Currier BS, Stefan R, Ratliff K, et al. Yeast beta-glucan supplementation downregulates markers of systemic inflammation after heated treadmill exercise. Nutrients. 2020;12:1144. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Evans M, Falcone PH, Crowley DC, Sulley AM, Campbell M, Zakaria N, et al. Effect of a Euglena gracilis fermentate on immune function in healthy, active adults: a randomized, double-blind, placebo-controlled trial. Nutrients. 2019;11:2926. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Dharsono T, Rudnicka K, Wilhelm M, Schoen C. Effects of yeast (1,3)-(1,6)-beta-Glucan on severity of upper respiratory tract infections: a double-blind, randomized, placebo-controlled study in healthy subjects. J Am Coll Nutr. 2019;38:40–50. [DOI] [PubMed] [Google Scholar]
- 27.MacFarlin BK, Carpenter KC, Davidson T, McFarlin MA. Baker’s yeast beta glucan supplementation increases salivary IgA and decreases cold/flu symptomatic days after intense exercise. J Diet Suppl. 2013;10:171–83. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Talbott SM, Talbott JA, Talbott TL, Dingler E. β-Glucan supplementation, allergy symptoms, and quality of life in self-described ragweed allergy sufferers. Food Sci Nutr. 2013;1:90–101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Talbott SM, Talbott JA. Baker’s yeast beta-glucan supplement reduces upper respiratory symptoms and improves mood state in stressed women. J Am Coll Nutr. 2012;31:295–300. [DOI] [PubMed] [Google Scholar]
- 30.Talbott S, Talbott J. Beta 1,3/1,6 glucan decreases upper respiratory tract infection symptoms and improves psychological well-being in moderate to highly-stressed subjects. Agro Food Ind Hi-Tec. 2010;21:21–4. [Google Scholar]
- 31.Feldman S, Schwartz HI, Kalman DS, Mayers A, Kohrman HM, Clemens R, et al. Randomized Phase II Clinical Trials of Wellmune WGP® for Immune Support During Cold and Flu Season. J Appl Res. 2009;9:30–42. [Google Scholar]
- 32.Kuraishi S, Kato M, Tsujioka B. Development of the “Uchida-Kuraepelin Psychodiagnostic Test” in Japan. Psychologia. 1957;1:104–9. [Google Scholar]
- 33.Tanaka M, Mizuno K, Tajima S, Sasabe T, Watanabe Y. Central nervous system fatigue alters autonomic nerve activity. Life Sci. 2009;84:235–9. [DOI] [PubMed] [Google Scholar]
- 34.GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime. 2024. https://gradepro.org/.
- 35.Aldwinckle J, Kristiansen B. A quality-of-life study in healthy adults supplemented with Lentinex® beta-glucan of Shiitake culinary-medicinal mushroom, Lentinus edodes (Agaricomycetes). Int J Med Mushrooms. 2020;22:407–15. [DOI] [PubMed] [Google Scholar]
- 36.Ishibashi K, Nishioka M, Onaka N, Takahashi M, Yamanaka D, Adachi Y, et al. Effects of Euglena gracilis EOD-1 ingestion on salivary IgA reactivity and health-related quality of life in humans. Nutrients. 2019;11:1144. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Mackinnon LT. Immunity in athletes. Int J Sports Med. 1997;18:S62–8. [DOI] [PubMed] [Google Scholar]
- 38.Cacioppo JT. Social neuroscience: autonomic, neuroendocrine, and immune responses to stress. Psychophysiology. 1994;31:113–28. [DOI] [PubMed] [Google Scholar]
- 39.Olini N, Rothfuchs I, Azzinnari D, Pryce CR, Kurth S, Huber R. Chronic social stress leads to altered sleep homeostasis in mice. Behav Brain Res. 2017;327:167–73. [DOI] [PubMed] [Google Scholar]
- 40.Castro EDM, Calder PC, Roche HM. β-1,3/1,6-glucans and immunity: state of the art and future directions. Mol Nutr Food Res. 2021;65:1901071. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, et al. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans. Blood. 2011;117:6825–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Neville V, Gleeson M, Folland JP. Salivary IgA as a risk factor for upper respiratory infections in elite professional athletes. Med Sci Sports Exerc. 2008;40:1228–36. [DOI] [PubMed] [Google Scholar]
- 43.Phillips AC, Carroll D, Evanc P, Bosch JA, Clow A, Hucklebridge F, et al. Stressful life events are associated with low secretion rates of immunoglobulin A in saliva in the middle aged and elderly. Brain Behav Immun. 2006;20:191–7. [DOI] [PubMed] [Google Scholar]
- 44.Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles—continuous outcomes. J Clin Epidemiol. 2013;66:173–83. [DOI] [PubMed] [Google Scholar]
- 45.Fukuda S, Nojima J, Motoki Y, Yamaguti K, Nakatomi Y, Okawa N, et al. A potential biomarker for fatigue: oxidative stress and anti-oxidative activity. Biol Psychol. 2016;118:88–93. [DOI] [PubMed] [Google Scholar]
- 46.Xu X, Ding Y, Yang Y, Gao Y, Sun Q, Liu J, et al. β-glucan salecan improves exercise performance and displays anti-fatigue effects through regulating energy metabolism and oxidative stress in mice. Nutrients. 2018;10:858. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Ojiri Y, Endoh H, Okumoto T, Atsuta K, Yoshinari O, Moriyama H. Randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of beta-1,3/1,6 glucan on stress associated with daily lifestyle in healthy subjects. Funct Foods Health Dis. 2015;5:145–54. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data utilized for all analyzes conducted in this manuscript are available from the figures and tables presented herein. Furthermore, the R package used for statistical analyses is accessible online, ensuring transparency and reproducibility of the findings.